– Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy…
Presentation highlights results from 13- and 39-week studies of eneboparatide in non-human primates demonstrating no evidence of deleterious impact on…
Cash on Hand of $15.5M Expected to Support Completion of the CAReS Trial and Operations into Second Half of 2024SOLANA…
Professors Einar Stefánsson and Thorsteinn Loftsson, Oculis’ co-founders, nominated in ‘Research’ category of prestigious European Patent Office awardsNominated in recognition…
Company maintains strong cash position of $231.6 millionSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc.…
Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins…
EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of…
-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE…
CONSHOHOCKEN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics…
-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition-WALTHAM, Mass.,…